The cardiovascular and other actions of angiotensin II (Ang II) are mediated by AT1 and AT2
receptors, which are seven transmembrane glycoproteins with 30% sequence similarity …

The four major classes of protease enzymes1-4 (aspartic, serine, cysteine, and metallo)
selectively catalyze the hydrolysis of polypeptide bonds. Their control over protein synthesis …

Blockade of the renin-angiotensin system began as a way of studying the pathogenesis of
cardiovascular disease with specific pharmacological probes. Oral activity, achieved by …

Angiotensin II receptor blockers (ARBs) represent a new class of effective and well tolerated
orally active antihypertensive agents. Recent clinical trials have shown the added benefits of …

For about half a century, the binding of drugs to plasma albumin, the “silent receptor,” has
been recognized as one of the major determinants of drug action, distribution, and …

Heart failure (HF) is characterized by the inability of systemic perfusion to meet the body's
metabolic demands and is usually caused by cardiac pump dysfunction and may …

Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. In
landmark clinical trials, pharmacological inhibition of the renin-angiotensin system (RAS) …

This review describes the clinical status (based on available information) of experimental
drugs that inhibit enzymes called proteases, or more precisely a sub-class of proteases …

Angiotensin II antagonists (AIIA) are part of a new rational treatment of hypertension.
Because adverse circulatory effects during anesthesia can occur in patients chronically …

Liver disease can modify the kinetics of drugs biotransformed by the liver. This review
updates recent developments in this field, with particular emphasis on cytochrome P450 …